Drilldown: Medicines

None (1) · Dexmethylphenidate (1) · Sildenafil (1)

Aduhelm (1) · Focalin, Focalin XR (1) · Viagra, Revatio (1)

Anti-amyloid beta (Aβ) monoclonal antibody (1) · CNS stimulant (1) · NDRI (1) · PDE5 Inhibitor (1) · Psychostimulant (1)

Human IgG1 monoclonal antibody targeting aggregated forms of amyloid-β (Aβ), soluble oligomers and insoluble fibrils. Reduces Aβ plaque burden on PET imaging via Fc-mediated microglial clearance. Whether plaque reduction translates to clinical benefit is the core controversy. (1) · Norepinephrine–dopamine reuptake inhibition (DAT, NET), d-threo enantiomer of methylphenidate (1) · Selective inhibitor of phosphodiesterase type 5 (PDE5), preventing cGMP breakdown in vascular smooth muscle. In the corpus cavernosum, potentiates the NO/cGMP cascade triggered by sexual stimulation. (1)

Alzheimer disease (FDA accelerated approval June 2021; '''withdrawn from market January 2024''' by manufacturer Biogen). At time of approval indicated for MCI or mild dementia stage of AD. (1) · '"`UNIQ--vote-00000150-QINU`"', '"`UNIQ--vote-00000151-QINU`"' (1) · '"`UNIQ--vote-00000705-QINU`"', '"`UNIQ--vote-00000706-QINU`"' (1)

None (1) · 50 mg ~1 h before sexual activity (ED); 20 mg TID (PAH) (1) · Was 1 mg/kg IV q4w × 2, then 3 mg/kg × 2, then 6 mg/kg × 2, then 10 mg/kg q4w (1)

None (1) · 25, 50, 100 mg tabs (Viagra); 20 mg tabs and 10 mg/mL oral suspension (Revatio) (1) · Was: 170 mg/1.7 mL, 300 mg/3 mL vials for IV infusion (1)

None (1) · 100 mg/d (ED); 20 mg TID (PAH) (1) · Withdrawn 2024 (1)

IV (Revatio) (1) · IV infusion every 4 weeks (1) · Oral (2)

None · Hours · 30-60 minutes · 1-2 hours · ~30 min · LDL lowering at 2 weeks, max by 4 weeks · ~1 hour · 15-30 minutes · 15–30 min · 1–2 h · 30–60 min · Antidepressant effect emerges over 1-2 weeks · BP and symptomatic LUTS improvement within 1-2 weeks · BP effect within 1-2 weeks · Clinical improvement within 24-72 hours · Days · Motor improvement over days at therapeutic dose · Over weeks · Postprandial glucose effect within days; HbA1c by 12 weeks · Sleep effect from first dose; antidepressant effect over 1-4 weeks

Other values:

Search

IR 4–6 h; XR 8–12 h (1) · Withdrawn (1) · ~4 h (1)

2.2 h (IR parent); ~3 h (XR parent) (1) · ~25 days (1) · ~4 h (1)

100% (IV) (1) · ~22–25% (1) · ~40% (1)

Category B (1) · Category C (1) · Discontinued/withdrawn (1)

Rx-only in US (1) · Schedule II (1) · Withdrawn from US market January 2024 (1)